0001209191-18-039316.txt : 20180622 0001209191-18-039316.hdr.sgml : 20180622 20180622191116 ACCESSION NUMBER: 0001209191-18-039316 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180620 FILED AS OF DATE: 20180622 DATE AS OF CHANGE: 20180622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nagler David CENTRAL INDEX KEY: 0001416175 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 18915641 MAIL ADDRESS: STREET 1: ARYX THERAPEUTICS,INC. STREET 2: 6300 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-20 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001416175 Nagler David C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 1 0 0 SVP, HR & Corp. Affairs Common Stock 2018-06-20 4 M 0 4700 2.1852 A 4700 D Common Stock 2018-06-20 4 S 0 4700 45.2457 D 0 D Common Stock 2018-06-20 4 M 0 300 2.1852 A 300 D Common Stock 2018-06-20 4 S 0 300 46.0201 D 0 D Stock Option (right to buy) 2.1852 2018-06-20 4 M 0 5000 0.00 D 2025-02-04 Common Stock 5000 32347 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. The lowest price at which shares were sold was $45.00 and the highest price at which shares were sold was $45.97. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Represents the weighted average sale price. The lowest price at which shares were sold was $46.00 and the highest price at which shares were sold was $46.06. The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. /s/ Thomas Soloway as attorney-in-fact for David Nagler 2018-06-22